Awards Nomination 20+ Million Readerbase
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Journal of Bioequivalence & Bioavailability
Comparison on the therapeutic action of coptis and bear bile on experimental liver fibrosis
4th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R&D Summit
May 20-22, 2013 DoubleTree by Hilton, Beijing, China

Ning Wang and Yibin Feng

Posters: J Bioequiv Availab

Abstract:

B ear bile is a Chinese Medicine that was used to treat liver diseases for thousands of years. However, the use of bear bile in Chinese Medicine clinical practice has received a lot of challenges since bears are currently endangered. It is a ethical problem that obtaining bile juice from the animals. Coptis is a Chinese Medicine that has been used to treat heat-related diseases in clinical practice and our clinical observation has found that Coptis is effective in curing liver diseases. The aim of study is to investigate if the therapeutic effect of Coptis is comparable with bear bile on the experimental hepatic fibrosis models. CCl 4 , bile duct ligation (BDL) and alcohol-induced liver fibrosis models were used in this study and the therapeutic effects of Coptis and bear bile were evaluated. The chemical composition of Coptis and bear bile was analyzed by high performance liquid chromatography (HPLC). It was observed that the major active components of Coptis was berberine and berberine-like alkaloids and the major compounds in bear bile was Tauroursodeoxycholic acid (TUDCA). Significant induction on the Hyp content, the biomarker of liver fibrosis in tissue, was observed (p < 0.05). Drug intervention could reduce the Hyp content in modeled rats (p < 0.05). The effect of Coptis is comparable with Bear bile (p > 0.05). However, it was observed that BB (TUDCA) might exhibit better effect in inhibiting Hyp content than Coptis did in hepatic fibrosis though no statistical significance could be found (p > 0.05). Both Coptis and Bear bile exhibited potent therapeutic effect regarding the combined scores based on the examination of hepatocyte death, inflammatory cell infiltration and fibrosis It was observed that both Coptis and Bear bile could completely combat the liver fibrosis induced by alcohol, while Bear bile exhibited better effect on chemical toxin CCl 4 -induced hepatic damage and fibrosis and Coptis showed potent action on BDL-induced fibrosis. In conclusion, the anti-fibrotic action of Coptis was comparable to bear bile on the all three experimental animal models. Coptis had the potential to replace bear bile for the treatment of liver diseases